FDA Approves NINTEDANIB CAPSULES, 100 MG AND 150 MG — EXELAN PHARMACEUTICALS INC.

# FDA Approves Generic Nintedanib Capsules; Exelan Pharmaceuticals Enters Competitive Pulmonary Fibrosis Market Exelan Pharmaceuticals Inc. has received FDA approval for generic nintedanib capsules in 100 mg and 150 mg strengths, marking a significant competitive entry into the pulmonary fibrosis treatment market and potentially increasing pricing pressure on the branded Ofev formulation. The approval is expected to expand patient access and drive cost savings for healthcare systems treating idiopathic pulmonary fibrosis and other related conditions.